Mark A Perazella1. 1. Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut 06520-8029, USA.
Abstract
PURPOSE OF REVIEW: Studies of a rare systemic fibrosing condition-entitled nephrogenic systemic fibrosis (NSF) are linked to gadolinium-based contrast (GBC) agent exposure in patients with advanced kidney disease. However, many patients with kidney disease are exposed to GBC agents, yet they do not develop this devastating disorder. RECENT FINDINGS: NSF appears more likely to develop when the combination of advanced kidney disease, linear GBC agent exposure, and the presence of unique patient features converge. Linear GBC agents are more likely to promote NSF, probably due to chelate-Gd binding instability +/- underlying proinflammatory effects. Patients with advanced acute or chronic kidney disease (CKD) are at highest risk, in contrast to those with lower stages of CKD (stages I-III). Finally, whereas exposure to GBC agents in patients with advanced kidney disease is required for NSF to develop, it does not appear sufficient. Additional patient-specific co-factors, such as metabolic disorders, vascular injury, and inflammation, may also be necessary for NSF to occur. SUMMARY: NSF develops when 'the perfect storm' of factors is present: unstable/pro-inflammatory GBC agent exposure, advanced kidney disease, and unique patient factors. Recognizing this combination of factors will hopefully allow this devastating condition to become of historical interest only.
PURPOSE OF REVIEW: Studies of a rare systemic fibrosing condition-entitled nephrogenic systemic fibrosis (NSF) are linked to gadolinium-based contrast (GBC) agent exposure in patients with advanced kidney disease. However, many patients with kidney disease are exposed to GBC agents, yet they do not develop this devastating disorder. RECENT FINDINGS: NSF appears more likely to develop when the combination of advanced kidney disease, linear GBC agent exposure, and the presence of unique patient features converge. Linear GBC agents are more likely to promote NSF, probably due to chelate-Gd binding instability +/- underlying proinflammatory effects. Patients with advanced acute or chronic kidney disease (CKD) are at highest risk, in contrast to those with lower stages of CKD (stages I-III). Finally, whereas exposure to GBC agents in patients with advanced kidney disease is required for NSF to develop, it does not appear sufficient. Additional patient-specific co-factors, such as metabolic disorders, vascular injury, and inflammation, may also be necessary for NSF to occur. SUMMARY: NSF develops when 'the perfect storm' of factors is present: unstable/pro-inflammatory GBC agent exposure, advanced kidney disease, and unique patient factors. Recognizing this combination of factors will hopefully allow this devastating condition to become of historical interest only.
Authors: Khaled Abdel-Kader; Priti R Patel; Alexander J Kallen; Ronda L Sinkowitz-Cochran; Warren K Bolton; Mark L Unruh Journal: Clin J Am Soc Nephrol Date: 2010-03-18 Impact factor: 8.237
Authors: Charles L Bennett; Karen M Starko; Henrik S Thomsen; Shawn Cowper; Oliver Sartor; Iain C Macdougall; Zaina P Qureshi; P Brandon Bookstaver; April D Miller; LeAnn B Norris; Sudha Xirasagar; Alyssa Trenery; Isaac Lopez; Adam Kahn; Alanna Murday; Stefano Luminari; Denis Cournoyer; Francesco Locatelli; Paul Ray; Donald R Mattison Journal: J Gen Intern Med Date: 2012-06-13 Impact factor: 5.128
Authors: Emmanuil Smorodinsky; David S Ansdell; Zeke W Foster; Sameer M Mazhar; Irene Cruite; Tanya Wolfson; Sebastian B Sugay; Gabriella Iussich; Masoud Shiehmorteza; Yuko Kono; Alexander Kuo; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2014-05-09 Impact factor: 4.813